

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.usspto.gov

APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/066,432	10/066,432 01/31/2002		Thomas F. Smith	07039-246001	5103	
26191	7590	02/12/2004		EXAMINER		
FISH & RI	CHARDS	SON P.C.	HORLICK, KENNETH R			
3300 DAIN 60 SOUTH			ART UNIT	PAPER NUMBER		
MINNEAP			1637			
				DATE MAIL ED. 02/12/200	4	

Please find below and/or attached an Office communication concerning this application or proceeding.

					·					
			Application No	<b>)</b> .	Applicant(s)					
			10/066,432		SMITH ET AL.					
	Office Action Summary		Examiner		Art Unit					
			Kenneth R Hor		1637					
Period fo	The MAILING DATE of this commun r Reply	ication app	ears on the cov	er sheet with the c	orrespondence ad	ldress				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status										
1)⊠	Responsive to communication(s) file	ed on <u>21 No</u>	ovember 2003.							
2a) <u></u>	This action is <b>FINAL</b> . 2b) This action is non-final.									
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.									
Dispositi	on of Claims									
5)□ 6)⊠ 7)□										
Applicati	on Papers									
10)	The specification is objected to by the The drawing(s) filed on is/are. Applicant may not request that any objected to Replacement drawing sheet(s) including the oath or declaration is objected to	: a) acce ection to the c g the correcti	epted or b)  odrawing(s) be he on is required if	ld in abeyance. See the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 Cl					
Priority u	nder 35 U.S.C. §§ 119 and 120									
12)  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a)  All b)  Some * c)  None of:  1.  Certified copies of the priority documents have been received.  2.  Certified copies of the priority documents have been received in Application No  3.  Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  13)  Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet.  37 CFR 1.78.  a)  The translation of the foreign language provisional application has been received.  14)  Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.										
	e of References Cited (PTO-892)		⊿۱۲	Interview Summary (	(PTO-413) Paper Note	e)				
2) 🔲 Notice	e of Draftsperson's Patent Drawing Review (Fnation Disclosure Statement(s) (PTO-1449) P		5) [	Notice of Informal Pa						

Application/Control Number: 10/066,432 Page 2

Art Unit: 1637

1. The specification is objected to because of the following informality: it contains active internet links. These must be deleted or modified so as not to be active.

- 2. Applicant's election without traverse of Group I, claims 1-33 and 45-53 in the paper filed 11/21/03 is acknowledged.
- 3. Claims 34-44 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the paper filed 11/21/03.
- 4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 5. Claim 31 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. This claim is confusing because "said portion" lacks proper antecedent basis. Correction is required.

6. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Claims 1-27 are rejected under 35 U.S.C. 102(a) as being anticipated by Espy et al. (J. Clin. Micro. Feb 2000).

Espy et al. clearly teach the claimed methods; see entire reference on pages 795-799. This is a reference to "others" as besides the four instant inventors, Espy et al. names three other authors.

- 7. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Application/Control Number: 10/066,432

Art Unit: 1637

Claims 1, 5-27, and 30-33 are rejected under 35 U.S.C. 103(a) as being unpatentable over Greenberg et al. (US 5,846,706) in view of Wittwer et al. (US 6,140,054).

These claims are drawn to methods comprising detection of HSV by PCR amplification of polymerase or TK nucleic acid sequences, and detection using two FRET-labeled oligonucleotide probes which hybridize adjacently on the amplified target nucleic acid.

Greenberg et al. disclose the detection of HSV using PCR and hybridization detection probes. The primers and probes target both the polymerase and TK genes, as required in the claims. This patent further discloses probes capable of distinguishing HSV-1 from HSV-2. See especially column 11, line 29 to column 12, line 38 and Example 2 in columns 13-14.

Greenberg et al. do not teach PCR combined with a detection system comprising two FRET-labeled oligonucleotide probes which hybridize adjacently on the amplified target nucleic acid.

Wittwer et al. disclose PCR combined with detection via two FRET-labeled oligonucleotide probes which hybridize adjacently on the amplified target nucleic acid, as well as melting temperature analysis to distinguish among variant target sequences (see column 2, lines 39-52; column 3, lines 19-40; column 4, lines 19-41; columns 11-19).

One of ordinary skill in the art would have been motivated to modify the HSV detection method of Greenberg et al. by using two FRET-labeled oligonucleotide probes

Art Unit: 1637

which hybridize adjacently on the amplified target nucleic acid because Wittwer et al. taught that such probe pairs provided an advantageous detection means. Thus, it would have been *prima facie* obvious to one of ordinary skill in the art at the time of the invention to carry out the claimed methods.

8. Claims 45-50 are rejected under 35 U.S.C. 103(a) as being unpatentable over Greenberg et al. (US 5,846,706) in view of Livak et al.

These claims are drawn to methods comprising detection of HSV by PCR amplification of polymerase nucleic acid sequences, and detection using a probe comprising two labels enabling FRET detection.

Greenberg et al. disclose the detection of HSV using PCR and hybridization detection probes. The primers and probes target both the polymerase and TK genes, as required in the claims. This patent further discloses probes capable of distinguishing HSV-1 from HSV-2. See especially column 11, line 29 to column 12, line 38 and Example 2 in columns 13-14.

Greenberg et al. do not teach PCR combined with a detection system comprising a probe having two labels enabling FRET detection.

Livak et al. disclose PCR combined with detection via a probe having two labels enabling FRET detection (see especially Figure 1 on page 358).

One of ordinary skill in the art would have been motivated to modify the HSV detection method of Greenberg et al. by using a probe having two labels enabling FRET detection because Livak et al. taught that such a probe provided an advantageous

Application/Control Number: 10/066,432

Art Unit: 1637

detection means. Thus, it would have been *prima facie* obvious to one of ordinary skill in the art at the time of the invention to carry out the claimed methods.

9. Claims 51-53 are rejected under 35 U.S.C. 103(a) as being unpatentable over Greenberg et al. (US 5,846,706) in view of Higuchi et al.

These claims are drawn to methods comprising detection of HSV by PCR amplification of polymerase nucleic acid sequences, and detection using a nucleic acid binding dye.

Greenberg et al. disclose the detection of HSV using PCR and hybridization detection probes. The primers and probes target both the polymerase and TK genes, as required in the claims. This patent further discloses probes capable of distinguishing HSV-1 from HSV-2. See especially column 11, line 29 to column 12, line 38 and Example 2 in columns 13-14.

Greenberg et al. do not teach PCR combined with a detection system comprising a binding dye.

Higuchi et al. disclose PCR combined with detection via a binding dye (see pages 413-416).

One of ordinary skill in the art would have been motivated to modify the HSV detection method of Greenberg et al. by using a nucleic acid binding dye because Higuchi et al. taught that such a dye provided an advantageous detection means. Thus, it would have been *prima facie* obvious to one of ordinary skill in the art at the time of the invention to carry out the claimed methods.

Application/Control Number: 10/066,432 Page 7

Art Unit: 1637

10. Claims 28 and 29 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. No prior art has been found teaching or suggesting HSV detection methods using the required primers or probes as set forth in the recited SEQ ID Nos.

- 11. No claims are allowable.
- 12. Piiparinen et al., which teaches PCR methods of genotyping HSV-1 and HSV-2 targeting the polymerase gene, and Heller, which discloses an oligonucleotide which comprises the sequence of instant SEQ ID NO:10, are made of record as references of interest.
- 13. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kenneth R Horlick whose telephone number is 571-272-0784. The examiner can normally be reached on Monday-Thursday 6:30AM-5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 571-272-0782 The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number: 10/066,432 Page 8

Art Unit: 1637

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Kenneth R Horlick Primary Examiner

Art Unit 1637

01/29/04